Pancreatic Cancer Research

ResearcherMarche Polytechnic UniversityActive in the last 2 years

Berina Šabanović

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0883-3248; OpenAlex author ID A5042441885. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1001↗
  2. Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. Co-author DOI 10.1016/j.xpro.2025.103635↗
  3. Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. Co-author DOI 10.1016/j.ymthe.2025.09.004↗
  4. Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. Co-author DOI 10.1002/advs.202308990↗
  5. CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. Co-author DOI 10.1016/j.xcrm.2024.101692↗
  6. Single-cell omics: a new perspective for early detection of pancreatic cancer? First author DOI 10.1016/j.ejca.2023.112940↗
  7. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
  8. Effects of the Exposure of Human Non-Tumour Cells to Sera of Pancreatic Cancer Patients. Co-author DOI 10.3390/biomedicines10102588↗
  9. Role of primary cilium in pancreatic ductal adenocarcinoma (Review). Co-author DOI 10.3892/ijo.2020.5121↗
  10. CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer? Co-author DOI 10.1155/2019/9681698↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher Heeschen · 7 shared papers, 2023–2026 · strength 1.31
  2. Chenlei Wen · 5 shared papers, 2024–2026 · strength 0.96
  3. Quan Zheng · 5 shared papers, 2023–2025 · strength 0.87
  4. Jiajia Tang · 4 shared papers, 2023–2025 · strength 0.68
  5. Baiyong Shen · 3 shared papers, 2024–2025 · strength 0.55
  6. Qi Wang · 3 shared papers, 2023–2025 · strength 0.54
  7. Da Fu · 3 shared papers, 2024–2025 · strength 0.50
  8. Matteo Giulietti · 3 shared papers, 2019–2022 · strength 0.48
  9. Francesco Piva · 3 shared papers, 2019–2022 · strength 0.48
  10. Baiyong Shen · 2 shared papers, 2024–2026 · strength 0.41
  11. Elisabetta Fenocchio · 2 shared papers, 2024–2025 · strength 0.33
  12. Yaru Zhao · 2 shared papers, 2024–2025 · strength 0.33
  13. Yu Jiang · 1 shared paper, 2026 · strength 0.24
  14. Miriam Roberto · 1 shared paper, 2026 · strength 0.24
  15. Jingwei Li · 1 shared paper, 2026 · strength 0.24
  16. Yuntao YANG · 1 shared paper, 2026 · strength 0.24
  17. Qian Yu · 1 shared paper, 2025 · strength 0.22
  18. Gaya Spolverato · 1 shared paper, 2022 · strength 0.17
  19. Renfei Wu · 1 shared paper, 2024 · strength 0.17
  20. Jingwei Li · 1 shared paper, 2024 · strength 0.17
  21. Lingxi Jiang · 1 shared paper, 2024 · strength 0.17
  22. Ke Jiang · 1 shared paper, 2024 · strength 0.15
  23. Diana Behrens · 1 shared paper, 2023 · strength 0.14
  24. Patricia Sancho · 1 shared paper, 2023 · strength 0.14
  25. Sonia Alcalá · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.